Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

バイオテクノロジー

Dr. Diane L. Berry Ph.D.

Executive Vice President and Chief of Global Policy & Advocacy Officer

Mr. Bilal  Arif

Executive Vice President & Chief Technical Operations Officer

Dr. Louise R. Rodino-Klapac Ph.D.

Executive Vice President, Chief Scientific Officer and Head of Research & Development

Mr. Ryan E. Brown J.D.

Executive Vice President, Chief General Counsel & Corporate Secretary

Ms. Alison  Nasisi

Executive Vice President & Chief People Officer

Mr. Will  Tilton

Senior Vice President, Head of Strategy & Chief of Staff

Mr. Dallan  Murray

Executive Vice President & Chief Customer Officer

Ms. Francesca T. Nolan

Executive Director of Investor Relations and Corporate Communications

Mr. Douglas S. Ingram Esq.

President, Chief Executive Officer & Director

Mr. Ian Michael Estepan

Executive Vice President & Chief Financial Officer

会社名	時価総額
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M
Starpharma Holdings Limited	0M

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. 競合他社リスト

主な競合企業